Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress
Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its participation in ...
Hosted on MSN3d
Atopic dermatitis market to reach $16.7b by 2030 across seven major markets
Pharmaceutical firms are urged to capitalise on current trends in AD trials. The atopic dermatitis (AD) market is projected ...
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...
Everyday Health5d
Ebglyss, a New Biologic Treatment for Atopic Dermatitis, Gets FDA Approval
Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...
The Pharma Letter4d
Atopic dermatitis market set for major growth
The atopic dermatitis (AD) market is projected to reach $16.7 billion by 2030, according to GlobalData. New therapies like ...
Medscape8d
FDA Approves Lebrikizumab for Atopic Dermatitis
The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for ...
The American Journal of Managed Care6d
FDA Approves Lebrikizumab For Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis
The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older ...
dermatologyadvisor2d
Pediatric Atopic Dermatitis: Dupilumab Normalizes Inflammatory Biomarkers
Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.
The Asian Parent on MSN9d
Atopic Dermatitis in Kids: What Every Parent Should Know
Atopic dermatitis, a chronic skin condition, is common in children and requires treatment to minimise frequent flares. Dr Ker ...
US FDA approves Elanco's skin disease treatment for dogs
The U.S. Food and Drug Administration has approved Elanco Animal Health's skin disease treatment for dogs, the health ...
Monthly Prescribing Reference3d
Adbry Autoinjector Now Available for Adults With Atopic Dermatitis
A new single-dose autoinjector presentation of Adbry ® (tralokinumab-ldrm) is now available for use in the treatment of moderate to severe atopic dermatitis not adequately controlled with topical ...